Sharp Therapeutics Corp.
SHRXF
$1.58
-$0.08-4.81%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.46% | -294.15% | 117.18% | -816.56% | 166.83% |
| Total Depreciation and Amortization | -7.94% | 9.57% | -14.50% | -40.75% | 931.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,023.96% | 103.81% | -198.18% | 209.76% | -12,015.79% |
| Change in Net Operating Assets | 521.72% | -639.02% | 116.12% | 1.42% | 26.39% |
| Cash from Operations | 12.78% | 16.85% | 3.38% | 5.06% | -68.47% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 82.57% | -473.60% |
| Issuance of Common Stock | 421.21% | -99.73% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | 64.06% | -101.78% | 4,964.20% | -100.98% | -- |
| Foreign Exchange rate Adjustments | -978.43% | -88.89% | 276.54% | -526.23% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -144.44% |
| Net Change in Cash | 10.44% | -202.11% | 177.16% | -145.58% | 10,782.43% |